Agenus Inc. (NASDAQ:AGEN) Receives $14.50 Average Target Price from Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN) have earned a consensus rating of “Hold” from the five brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $14.50.

AGEN has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Agenus in a research report on Saturday, September 27th. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Agenus in a research note on Wednesday, September 10th. Wall Street Zen lowered Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Zacks Research raised Agenus to a “hold” rating in a report on Tuesday, August 12th.

Agenus Price Performance

Shares of Agenus stock opened at $4.14 on Friday. Agenus has a 1 year low of $1.38 and a 1 year high of $7.34. The firm’s 50-day moving average is $4.59 and its 200 day moving average is $4.07. The stock has a market cap of $131.90 million, a price-to-earnings ratio of -0.58 and a beta of 1.43.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The business had revenue of $25.70 million for the quarter, compared to analyst estimates of $49.71 million. On average, equities analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Trading of Agenus

A number of institutional investors have recently made changes to their positions in the stock. Catalyst Funds Management Pty Ltd purchased a new position in shares of Agenus during the second quarter valued at approximately $50,000. Jump Financial LLC bought a new stake in Agenus in the 2nd quarter worth approximately $55,000. Savant Capital LLC purchased a new stake in Agenus during the 2nd quarter valued at $73,000. Bank of Montreal Can purchased a new stake in Agenus during the 2nd quarter valued at $75,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in shares of Agenus during the 2nd quarter valued at $85,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.